# Insight Molecular Diagnostics (formerly Oncocyte)

Source: https://onco.cc/companies/insight-molecular-diagnostics/  
OnCo record `insight-molecular-diagnostics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Insight Molecular Diagnostics, the renamed Oncocyte, is a small listed company whose cancer tests read gene activity in tumours to predict who will respond to immunotherapy, alongside a larger business in transplant rejection blood tests.

## Summary

Insight Molecular Diagnostics (iMDx), Nasdaq: IMDX, is the former Oncocyte Corporation, which changed its name and moved from Irvine, California to Nashville, Tennessee in June 2025. Its oncology assets include DetermaIO, a 27-gene expression assay of the tumour immune microenvironment intended to predict response to immune checkpoint inhibitors, and DetermaCNI, an in-development blood test measuring genomic copy number instability in circulating tumour DNA to monitor treatment response. The commercial focus has shifted to transplant monitoring with the GraftAssure donor-derived cell-free DNA tests: GraftAssureCore is a laboratory developed test, GraftAssureIQ a research kit and GraftAssureDx is under FDA review for kidney transplant recipients, with a favourable Medicare coverage decision in July 2026. At the end of Q2 2026 the company held $18.7 million in cash.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Nashville, TN
- Type: diagnostics
- Website: https://imdxinc.com/
- Ticker: IMDX

## Notes

- Oncology is now a minority of the business; transplant testing dominates. Financing amounts for the warrant issuances were not stated in the fetched release so no rounds are recorded. Ticker was OCX before the rename.

## Sources

- Official website: https://imdxinc.com/
- Investor relations: https://investors.imdxinc.com/
- Q2 2026 results release (Nashville dateline, former name): https://investors.imdxinc.com/news-releases/2026/08-10-2026-210715920

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/)

---
JSON: https://onco.cc/api/v1/entities/insight-molecular-diagnostics.json